This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Bavencio
  • /
  • Avelumab in Subjects With Merkel Cell Carcinoma (J...
Clinical trial

Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)

Read time: 1 mins
Last updated:2nd Jul 2014
Identifier: NCT02155647

This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in subjects with metastatic Merkel cell carcinoma (MCC).

Study Type: Interventional
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma
Estimated Enrollment: 200
Actual Study Start Date: July 3, 2014
Estimated Study Completion Date: June 30, 2025
Estimated Primary Completion Date: September 27, 2019 (Final data collection date for primary outcome measure)

- Experimental:

Category Value
Date last updated at source 2017-08-22
Study type(s) Interventional
Expected enrolment 200
Study start date 2014-07-03
Estimated primary completion date 2019-09-27

View full details